Lv11
16 积分 2023-11-06 加入
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
3小时前
已完结
Preclinical data supporting the differentiated profile of STAR-0310, a novel OX40 antagonistic monoclonal antibody
6小时前
已完结
Depletion of B Cells in Murine Lupus: Efficacy and Resistance
21天前
已完结
Remibrutinib in Chronic Spontaneous Urticaria
28天前
已完结
Spatial transcriptomic profiling reveals the pathophysiology of early-stage hidradenitis suppurativa
1个月前
已完结
Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape‐strips and biopsies
1个月前
已完结
Adverse Effects Versus Non-adverse Effects in Toxicology
1个月前
已完结
BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells
1个月前
已完结
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study
1个月前
已完结
The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety
1个月前
已完结
皖公网安备34019202002308
